Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$200.47 USD

200.47
3,531,078

-3.08 (-1.51%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $200.75 +0.28 (0.14%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks News

Eli Lilly's Olumiant Gets FDA Nod for Rheumatoid Arthritis

Eli Lilly (LLY) and its partner Incyte announce approval of their arthritis drug, Olumiant, in the United States. The drug will be available at two-fifth of the price of leading RA drugs.

    Gilead & Galapagos Announce Positive Data on Filgotinib

    Gilead (GILD) and partner Galapagaos (GLPG) announces positive data on filgotinib for the treatment of psoriatic arthritis in adults and ulcerative colitis.

      Pfizer's Arthritis Drug Gets FDA Nod for Ulcerative Colitis

      The FDA approves Pfizer's (PFE) sNDA seeking label expansion in third indication for Xeljanz to include moderately to severely active ulcerative colitis.

        AstraZeneca (AZN) Stock on Growth Path This Year: Here's Why

        AstraZeneca's (AZN) stock is up this year while the Large-Cap Pharma industry is witnessing a decline

          What's in Store for Cooper Companies' (COO) Q2 Earnings?

          Cooper Companies' (COO) Q2 results are likely to reflect solid segmental growth; intense competition is a concern.

            AbbVie (ABBV) Up 5.9% Since Earnings Report: Can It Continue?

            AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

              AbbVie's Imbruvica's Phase III Study Meets Primary Endpoint

              AbbVie's (ABBV) phase III iLLUMINA study evaluating Imbruvica in combination with Gazyva meets its primary endpoint of improvement in progression-free survival.

                Is the Options Market Predicting a Spike in AbbVie (ABBV) Stock?

                Investors in AbbVie (ABBV) need to pay close attention to the stock based on moves in the options market lately.

                  Eli Lilly Gets FDA Approval for Taltz in Genital Psoriasis

                  Eli Lilly (LLY) gets FDA approval for label expansion of its psoriasis injection Taltz to include data for psoriasis involving the genital area.

                    The Zacks Analyst Blog Highlights: Procter & Gamble, AbbVie, McDonald???s and PepsiCo

                    The Zacks Analyst Blog Highlights: Procter & Gamble, AbbVie, McDonald???s and PepsiCo

                      The Zacks Analyst Blog Highlights: Procter & Gamble, AbbVie, McDonald???s and PepsiCo

                      The Zacks Analyst Blog Highlights: Procter & Gamble, AbbVie, McDonald???s and PepsiCo

                        Roche (RHHBY) Announces Positive Data on Hemophilia Drug

                        Roche (RHHBY) announces positive data from two phase III studies on hemophilia drug Hemlibra which has further strengthened its hemophilia portfolio.

                          Madeleine Johnson headshot

                          Bear of the Day: Scotts Miracle-Gro (SMG)

                          After disappointing earnings, can a budding marijuana business boost this lawncare stock?

                            Gilead (GILD) Q1 Earnings & Sales Miss Estimates on Weak HCV

                            Gilead (GILD) announced dismal results for the first-quarter as HCV sales plunged further due to increasing competition.

                              Drug Stocks Q1 Earnings to Watch on May 1: PFE, MRK & More

                              Four pharma/biotech companies are set to release earnings report on May 1. Let's take a look into how the companies are placed ahead of the upcoming results.

                                HIV Segment to Aid Gilead (GILD) Beat Q1 Earnings Estimates?

                                Gilead (GILD) is likely to report an earnings beat in the first-quarter (results due on May 1) driven by its HIV franchise strength.

                                  DaVIta (DVA) to Report Q1 Earnings: Is a Beat in Store?

                                  Kidney Care Business and increasing number of dialysis centers are likely to boost DaVita's (DVA) earnings in Q1.

                                    AbbVie (ABBV) Q1 Earnings Beat, 2018 View Up, Stock Gains

                                    AbbVie's (ABBV) Q1 earnings top estimates with revenues marginally beating the same. Sales of the company's lead marketed drug, Humira, also rise year over year.

                                      Is a Beat in the Cards for Gilead (GILD) in Q1 Earnings?

                                      Gilead (GILD) is likely to beat earnings estimates when it reports first-quarter results on May 1 driven by strong HIV sales.

                                        Debapriya Chakraborty headshot

                                        AbbVie (ABBV) Tops Q1 Earnings and Revenues, View Up

                                        AbbVie's (ABBV) first-quarter 2018 earnings surpassed estimates with revenues marginally beating the same. Sales of its lead marketed drug Humira also increased compared to year ago figure.

                                          What's in the Cards for Inogen (INGN) This Earnings Season?

                                          Inherent benefits of POCs, direct-to-customer business model, underpenetrated international markets and expanding product portfolio are key growth catalysts for Inogen (INGN) in Q1.

                                            Drug Stock Q1 Earnings Due on Apr 26: ABBV, ALXN, BMY & VRTX

                                            Four pharma/biotech companies are set to release earnings report on Apr 26. Let's take a look into how the companies are placed ahead of the upcoming results.

                                              Is a Beat in the Cards for AbbVie (ABBV) in Q1 Earnings?

                                              Impressive sales rise of AbbVie's (ABBV) key drugs, Humira and Imbruvica, might lead the company to an earnings beat in Q1.

                                                Biogen (BIIB) Q1 Earnings Beat, Sales Miss, Shares Down

                                                Biogen's (BIIB) earnings beat estimates but sales miss the same marginally in Q1. The company's latest key drug Spinraza's tepid sales compares with its sequential tally.

                                                  What's in Store for AmerisourceBergen (ABC) in Q2 Earnings?

                                                  Despite solid prospects in the Pharmaceutical Distribution segment, a temporary slowdown in the PharMEDium unit is likely to mar AmerisourceBergen's (ABC) Q2 earnings.